MedTrace Logo

Genetic Characteristics of Metastatic Breast Cancer Patients

NCT04258735 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2020-02-06

No results posted yet for this study

Summary

Genomic analysis for metastatic breast cancer(MBC) patients

* Participant (Inclusion criteria)

1. Patients who diagnosed metastatic/stage IV breast cancer
2. Patients who were not received treatment for metastatic breast cancer on palliative setting
* Process

(1) Tissue/ Blood sample
* At diagnosis, MBC tissue / blood sample (20cc) will be obtained.
* At disease progression after 1st line treatment for MBC, blood sample (20cc) will be obtained (tissue; optional)

(2) WES, RNASeq, ctDNA, Exosome
* We will analyze genomic characteritics using WES, RNASeq, ctDNA, Exosome.

Conditions

Interventions

DIAGNOSTIC_TEST

Genomic analysis

WES, RNASeq, ctDNA, Exosome

Sponsors & Collaborators

  • Samsung Medical Center

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-17
Primary Completion
2024-07-31
Completion
2024-07-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04258735 on ClinicalTrials.gov